Apogee Therapeutics Has Initiated Dosing Of Healthy Volunteers In Its First Clinical Trial For APG990, A Novel, Subcutaneous Half-life Extended Monoclonal Antibody Targeting OX40L, Which Is Being Developed Initially For Atopic Dermatitis
Apogee Therapeutics Has Initiated Dosing Of Healthy Volunteers In Its First Clinical Trial For APG990, A Novel, Subcutaneous Half-life Extended Monoclonal Antibody Targeting OX40L, Which Is Being Developed Initially For Atopic Dermatitis
Apogee Therapeutics已開始在健康志願者中進行首個臨床試驗，研究APG990，一種新型皮下半衰期延長的單克隆抗體，其靶向物是OX40L，首先是爲特應性皮炎研發。
Apogee Therapeutics Has Initiated Dosing Of Healthy Volunteers In Its First Clinical Trial For APG990, A Novel, Subcutaneous Half-life Extended Monoclonal Antibody Targeting OX40L, Which Is Being Developed Initially For Atopic Dermatitis
Apogee Therapeutics已開始在健康志願者中進行首個臨床試驗，研究APG990，一種新型皮下半衰期延長的單克隆抗體，其靶向物是OX40L，首先是爲特應性皮炎研發。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間